Plain-English translation of NCT06651281 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Crohn Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is an extension study for people who have already been testing in earlier research trials for Crohn's disease or ulcerative colitis. Researchers want to continue observing how safe this medication is and how well patients tolerate it when taking it over a longer time period. You would receive either a low or high dose of the medication by injection under the skin.
Earlier studies showed promising results with this medication, and doctors need to understand how it performs and how safe it remains when people take it for months or even years. This long-term information helps determine whether the medication is truly ready for regular use in patients with these serious digestive conditions.
You likely qualify if…
You likely don't qualify if…
You would continue receiving the same type of medication you were taking in your earlier trial—either a low or high dose delivered by injection under the skin. Some participants will know exactly which dose they're receiving, while others will be in a blinded group where the research team knows the dose but you don't (this helps keep results unbiased). You'll attend regular study visits so researchers can monitor your safety and how well you tolerate the treatment over time.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States